Merck & Co taps China's genomics expertise as it formalises alliance with BGI
This article was originally published in Scrip
Merck & Co and the Chinese genomics company BGI have built on a statement of intent they signed around a year ago by entering into a formal collaboration to develop biomarkers and other genomic technologies with potential applications in drug discovery and diagnostics.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.